If your institution subscribes to this resource, and you don't have an Access Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.
Download the Access App here: iOS and Android. Learn more here!
Braftovi161-163,#
Antineoplastic, multikinase inhibitor
BRAF-positive (V600E or V600K) metastatic melanoma† (in combination with binimetinib)
Dabrafenib, vemurafenib
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Inhibitors of RAF Kinase: Vemurafenib, Dabrafenib
eChapter 2018: The Goodman & Gilman Year in Review New and Noteworthy FDA Approvals